Anthony Manning, PhD
Member of the Scientific Advisory Board
Anthony Manning has contributed to the approval of two drugs for the treatment of autoimmune disease and has led teams in the discovery of multiple small molecules and biologic therapeutics in clinical development. After a 30-year career in the pharmaceutical and biotechnology industry, Tony is currently the Principal at Manning Bio Worldwide, LLC where he assists biotechnology companies and academic institutions to develop transformative medicines.
Until 2020 Tony was Chief Scientific Officer at Momenta Pharmaceuticals, where he built a pipeline of first-in-class therapeutics for treating rare autoantibody-driven diseases. Within five years, teams led by Tony discovered three novel product candidates that entered clinical trials in multiple indications. Nipocalimab, an anti-FcRn monoclonal antibody, is currently in multiple Phase 3 clinical trials and received Orphan Drug and Fast track designations from the US FDA. Janssen Pharmaceuticals acquired Momenta in 2020 for $6.5bn.
Earlier in his career, Tony led drug discovery and development efforts at Roche Pharmaceuticals, contributing to the approvals of both Actemra and Rituxan for treating rheumatoid arthritis and other autoimmune diseases and helping create a pipeline of novel therapeutics for inflammatory and autoimmune diseases. Tony also led Immunology Research at Biogen Idec and contributed to the development of risk-mitigation strategies for managing side effects of Tysabri. Litifilimab, and anti-BDCA2 monoclonal antibody, is currently in Phase 3 development for Systemic Lupus Erythematosus. Tony also led drug discovery efforts at Pharmacia (acquired by Pfizer), Signal Pharmaceuticals (acquired by Celgene), and Aileron Therapeutics.
Tony also serves as a Board Director for Palatin Technologies, is a founder and Chairman of the non-profit Institute for Biomedical Entrepreneurship and serves as a Scientific Advisory Board member and consultant for a number of companies, including the Harvard Medical School Therapeutics Initiative and the Blavatnik Biomedical Accelerator.